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Comparative efficacy of caffeic acid phenethyl ester (CAPE),
olopatadine hydrochloride, and dexamethasone
sodium phosphate in experimental allergic conjunctivitis*
Erdinç AYDIN1, Helin DENİZ DEMİR1, Hüseyin ÖZYURT2, Ünal ERKORKMAZ3

Aim: To compare the antiallergic efficacy of 1% caffeic acid phenethyl ester (CAPE), 0.1% olopatadine hydrochloride,
and 0.1% dexamethasone sodium phosphate.
Materials and methods: Experimental allergic conjunctivitis was provoked by a mast cell activator (compound 48/80)
in 31 New Zealand rabbits. The rabbits were divided into 3 groups, and 1% CAPE, 0.1% olopatadine hydrochloride, and
0.1% dexamethasone sodium phosphate were instilled 30 min before and 15 min after the provocation. The edema and
hyperemia in the experimental (right) eyes and control (left) eyes were scored in each group. Anterior segment
photographs and conjunctival samples for histopathological evaluation and scoring were taken.
Results: When the edema and hyperemia scores of the postprovocation term were compared with those of the
provocation term, a significant difference was detected in each group (P = 0.021, P = 0.037, P = 0.0001). The
histopathological scores of the provocation and postprovocation terms were evaluated; a statistically significant difference
was found in the CAPE and dexamethasone sodium phosphate groups (P = 0.003, P = 0.014), but not in the olopatadine
group (P = 0.096).
Conclusion: This study demonstrated that 1% CAPE was as clinically efficacious as 0.1% olopatadine and 0.1%
dexamethasone. Thus, 1% CAPE may be an alternative to 0.1% olopatadine and 0.1% dexamethasone in the management
of acute allergic reactions.
Key words: Allergic conjunctivitis, caffeic acid phenethyl ester, dexamethasone sodium phosphate, olopatadine
hydrochloride

Deneysel alerjik konjonktivit modelinde kafeik asit feniletil ester (CAPE),
olopatadine hidroklorid ve deksametazon sodyum fosfat’ın
etkinliklerinin karşılaştırılması
Amaç: % 1 kafeik asit feniletil ester (CAPE), % 0,1 olopatidine hidroklorür ve % 0,1 deksametazon sodyum fosfat’ın antialerjik etkinliğinin karşılaştırılması.
Yöntem ve gereç: Deneysel alerjik konjonktivit üç gruba ayrılmış 31 Yeni Zelanda tipi tavşanlarda bir mast hücre
aktivatörü olan 48/80 bileşik ile oluşturuldu. % 1 CAPE, % 0,1 olopatidine hidroklorür ve % 0,1 deksametazon sodyum
fosfat provokasyondan 30 dakika önce, provokasyondan 15 dakika sonra damlatıldı. Her bir grupta çalışma (sağ) ve
kontrol (sol) gözlerinde ödem ve hiperemi derecelendirildi. Ön segment fotoğrafları ve histopatolojik değerlendirme
için konjunktiva örnekleri alındı ve derecelendirildi.
Bulgular: Provokasyon sonrası dönemde ödem ve hiperemi skorları provokasyon dönemi ile karşılaştırıldığında her
grupta anlamlı farklılık belirlendi (P = 0,021; P = 0,037; P = 0,0001). provokasyon dönemi ve provokasyon sonrası
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dönemde histopatolojik skorlar değerlendirildiğinde, CAPE ve deksametazon sodyum fosfat gruplarında istatistiki
anlamlı farklılık bulunurken (P = 0,003; P = 0,014), olopatidine grubunda mevcut değildi (P = 0,096).
Sonuç: Bu çalışma % 1 CAPE’nin klinik olarak % 0,1 olopatidine ve % 0,1 deksametazon kadar etkili olduğunu
göstermektedir. % 1 CAPE, akut alerjik konjonktivitin kontrol altına alınmasında % 0,1 olopatidine ve % 0,1
deksametazon’a bir alternatif olabilir.
Anahtar sözcükler: Alerjik konjunktivit, kafeik asit feniletil ester, deksametazon sodyum fosfat, olopatidin hidroklorür

Introduction
Allergic conjunctivitis is one of the most common
ocular conditions encountered by clinicians. The
pathogenesis of ocular allergy involves various
mechanisms that result in mast cell degranulation and
the release of mediators. These mediators lead to
itching, conjunctival vasodilatation, increased
vascular permeability, leukocyte chemotaxis, and
ocular surface alterations (1, 2). Type 1
hypersensitivity has early and late periods.
Vasodilatation and increased vascular permeability
are the hallmarks of the early period and present
themselves as severe itching, conjunctival injection,
chemosis, and tearing. The selective H1 receptor is
mainly responsible for itching, while the stimulation
of the H2 receptor results in redness. The early period
reactions are elicited within 5-30 min and then
disappear slowly. Late period reactions initiate within
2-6 h without exposure to additional antigens, and
inflammation is elevated by secondary mediators (3).
Mast cell stabilizers, H1 selective receptor blockers,
nonsteroidal antiinflammatory drugs, and steroids
have been commonly used for the treatment of
allergic conjunctivitis. Alleviating this condition is an
active area of research. Interventional studies of novel
antiallergic drugs are still continuing.
Caffeic acid phenethyl ester (CAPE) and its
analogs are found in various kinds of vegetative plant
materials and fruits. The compounds are known to
have antibacterial, antiviral, antiinflammatory,
antiatherosclerotic, antioxidative, antiproliferative,
immunostimulatory, and neuroprotective properties
(4-10). The antiallergic effects of CAPE are unknown.
In the present study, we investigated the antiallergic
effects of CAPE and compared our data with the
effects of 0.1% olopatadine hydrochloride and 0.1%
dexamethasone sodium phosphate.
606

Materials and methods
Reagents and equipment
Compound 48/80, as a mast cell activator, and
CAPE, as an inhibitor agent, were purchased from
Sigma (St. Louis, MO, USA). The 1% CAPE, 0.1%
olopatadine hydrochloride (Patanol®, Alcon), and
0.1% dexamethasone sodium phosphate (Maxidex®,
Alcon) were instilled into the experimental eyes, and
their solvents alone were instilled into the control
eyes.
Experimental Allergic Conjunctivitis
Animals were maintained and treated according
to the Association for Research in Vision and
Ophthalmology Resolution on the Use of Animals in
Research. The experimental allergic conjunctivitis in
31 New Zealand albino male rabbits weighing 1.5-2.5
kg was provoked by a mast cell activator (compound
48/80). All animals were anesthetized by
intramuscular injection of ketamine hydrochloride
(25 mg/kg, Ketalar®) and locally by topical 0.4%
oxybuprocaine hydrochloride (Benoxinate®), and then
they were divided into 3 groups.
Thirty minutes before the provocation by
compound 48/80 (50 mg/mL), each drug was applied
as a pretreatment to the right eyes. Left eyes were used
as controls and solvents of the agents were instilled.
The same procedure (second instillation) was
performed 15 min after the provocation. Group 1 (n
= 11) received 1% CAPE, group 2 (n = 10) received
0.1% dexamethasone sodium phosphate, and group 3
(n = 10) received 0.1% olopatadine hydrochloride in
the experimental (right) eyes.
The bulbar and tarsal conjunctival edema and
hyperemia in both eyes were scored at the 1st and
30th minutes after the provocation. Edema and
hyperemia were evaluated according to the scale
described by Abelson (Hyperemia: 0 = no hyperemia,
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1 = mild, 2 = moderate, 3 = severe, 4 = extremely
severe. Chemosis: 0 = none, 1 = mild, 2 = moderate,
3 = severe) (11). Scoring was performed by 2 trained
observers. The average of the conjunctival edema and
hyperemia scores was defined as the conjunctival
inflammation score. Immediately after scoring, the
physical appearances of the eye, including the
periocular region anterior segment, were
photographed for each group immediately after the
provocation and 15 min after the second instillation.
Histopathology
After sacrificing the animals, lids with conjunctiva
were excised. These tissues were fixed in 10% buffered
formaldehyde for 4 days and then were embedded in
paraffin. Prepared sections, 4 μm thick, were stained
with hematoxylin and eosin stain (H&E) and
examined under a light microscope under 200× and
400× magnifications. The conjunctival inflammation
score, characterized by the infiltration of
inflammatory cells (neutrophil and eosinophil
polymorph nuclear lymphocytes), was calculated
according to the following criteria by 2 trained
observers: no cells = 1, mild infiltration = 2, moderate
infiltration = 3, severe infiltration = 4.
Statistical Analysis
The Kolmogorov-Smirnov test was used to
evaluate the distribution of variables. If the
distribution was normal, a 2 independent sample ttest was used to compare the clinical and pathological
scores between the experimental and control groups.
The paired sample t-test was used to compare the
clinical and pathological scores of the provocation and
postprovocation terms. The repeated measures 2-way
ANOVA test was used to analyze the clinical and
pathological scores of the experimental and control
groups. The continuous variables were presented as
means and standard deviations. A P-value less than
0.05 was considered significant. Analyses were
performed using commercial software (SPSS 15.0
demo, Chicago, IL, USA).
Results
In our study, we scored the bulbar and tarsal
conjunctival edema and hyperemia in both eyes at the

1st and 30th minutes of the postprovocation term,
according to the scale mentioned before. The mean ±
SD (range) of conjunctival edema and hyperemia
scores for the provocation term and 30 min after the
provocation was, respectively, 2.63 ± 0.59 (1.5-3.5)
and 1.77 ± 0.46 (1-2.5) in the CAPE group, 2.95 ± 0.64
(1.5-3.5) and 1.90 ± 0.61 (1-2.5) in the olopatadine
hydrochloride group, and 3.05 ± 0.55 (2-3.5) and 1.95
± 0.15 (1.5-2.0) in the dexamethasone sodium
phosphate group experimental eyes. The
corresponding scores in the control eyes were 2.59 ±
0.58 (1.5-3.5) and 2.27 ± 0.47 (1.5-3.0) in the CAPE
group, 2.95 ± 0.60 (1.5-3.5) and 2.50 ± 0.58 (1.5-3.5)
in the olopatadine hydrochloride group, and 3.15 ±
0.47 (2.5-3.5) and 2.75 ± 0.42 (2.0-3.5) in
dexamethasone
sodium
phosphate
group,
respectively. The mean ± SD (range) of the pathologic
scores at the 1st and 30th minutes of the
postprovocation term were, respectively, 2.72 ± 0.78
(2.0-4.0) and 1.90 ± 0.30 (1.0-4.0) in the CAPE group,
3.10 ± 0.73 (2.0-4.0) and 2.10 ± 0.73 (1.0-3.0) in the
olopatadine hydrochloride group, and 3.10 ± 0.87
(2.0-4.0) and 2.0 ± 0.47 (1.0-3.0) in the
dexamethasone sodium phosphate group in the
experimental eyes. The corresponding scores in the
control eyes were 2.82 ± 0.75 (2-4) and 2.55 ± 0.52 (23) in the CAPE group, 2.9 ± 0.57 (2-4) and 2.6 ± 0.52
(2-3) in the olopatadine hydrochloride group, and 2.9
± 0.74 (2-4) and 2.6 ± 0.52 (2-3) in the dexamethasone
sodium phosphate group.
When the clinical scores of the postprovocation
term were compared with the provocation term scores
for the experimental eyes and control eyes, statistically
significant differences were detected in all groups. For
CAPE,
olopatadine
hydrochloride,
and
dexamethasone sodium phosphate, P = 0.001, P =
0.001, and P = 0.001; and P = 0.002, P = 0.004, and P
= 0.011 for the experimental and control eyes,
respectively (Table 1) (Figures 1 and 2).
When the clinical scores of the experimental and
control eyes were compared for the provocation term
and the postprovocation term, statistically significant
differences were only detected for the postprovocation
term in all groups (P = 0.021, P = 0.0001, and P =
0.037, respectively) (Table 1).
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Table 1. Clinical scores of study and control eyes for the provocation and postprovocation terms.
Study Eye

Control Eye

Clinical Scores

CAPE

Provocation Term
Postprovocation Term

Mean

SD

Mean

SD

2.63
1.77

0.60
0.47

2.59
2.27

0.58
0.47

§
t = 4.811, P = 0.001

O

Provocation Term
Postprovocation Term

2.95
1.90

0.64
0.62

§
t = 5.659, P < 0.001

Dx

Provocation Term
Postprovocation Term

3.05
1.95

0.55
0.16

§
t = 5.547, P < 0.001

t

¶

P

0.181
-2.510

0.858
0.021

0.000
-2.250

1.000
0.037

-0.435
5.580

0.669
<0.001

t§ = 4.183, P = 0.002
2.95
2.50

0.60
0.58

t§ = 3.207, P = 0.011
3.15
2.75

0.47
0.42

t§ = 3.857, P = 0.004

CAPE: caffeic acid phenethyl ester, O: olopatadine hydrochloride, Dx: dexamethasone sodium phosphate.
¶
§

: Two independent samples’ t-test result (the comparison between the study and control eyes).

: Paired samples’ t-test result (the comparison between the pre- and postprovocation terms).

Figure 1. Pictures of eyes in the provocation term, a: 1% CAPE, b: 0.1% olopatadine hydrochloride, c: 0.1% dexamethasone sodium
phosphate.

Figure 2. Pictures of eyes showing the reduction of conjunctival edema, hyperemia, and ocular mucus following instillation of agents in
the postprovocation term, a: 1% CAPE, b: 0.1% olopatadine hydrochloride, c: 0.1% dexamethasone sodium phosphate.
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When the pathological scores of the
postprovocation term were compared with the
provocation term for the experimental and control
eyes, there were statistically significant differences
observed in the experimental eyes but not in the
control eyes. For CAPE, olopatadine hydrochloride,

and dexamethasone sodium phosphate, P = 0.011, P =
0.007, and P = 0.001, respectively (Table 2) (Figures
3-8).
When the pathology scores of the experimental
and control eyes were compared for the provocation
term and the postprovocation term, statistically

Table 2. Pathological scores of study and control eyes for the provocation and postprovocation terms.
Study Eye

Control Eye

Pathological Scores

CAPE

Provocation Term
Postprovocation Term

SD

Mean

SD

2.72
1.91

0.79
0.30

2.82
2.55

0.75
0.52

§
t = 3.105, P = 0.011

O

Provocation Term
Postprovocation Term

3.10
2.10

0.74
0.74

§
t = 6.708, P < 0.001

Dx

Provocation Term
Postprovocation Term

¶

P

-0.277
-3.500

0.784
0.003

0.679
-1.756

0.506
0.096

0.552
-2.714

0.588
0.014

t
Mean

3.10
2.00

0.88
0.47

§
t = 3.498, P = 0.007

t§ = 1.936, P = 0.082
2.90
2.60

0.57
0.52

t§ = 1.964, P = 0.081
2.90
2.60

0.74
0.52

t§ = 1.406, P = 0.193

CAPE: caffeic acid phenethyl ester, O: olopatadine hydrochloride, Dx: dexamethasone sodium phosphate.
¶
: Two independent samples’ t-test result (the comparison between study and control eyes).
§
: Paired samples’ t-test result (the comparison between pre- and postprovocation terms).

Figure 3. Stromal edema and superficial, mild infiltration of
eosinophils and mononuclear leukocytes in the
conjunctiva in the provocation term of the CAPE group
(H&E ×5).

Figure 4. Lymphoid
follicle
formed
an
intensive
lymphoplasmacytic cell infiltration and scattered
eosinophilic leukocytes in the superficial portion of the
conjunctiva following instillation of agents in the
postprovocation term of the CAPE group (H&E ×20).
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Figure 5. Superficial mild mononuclear and more rarely
polymorphonuclear leukocyte cell infiltration in the
edematous stroma of the conjunctiva in the provocation
term of the olopatadine hydrochloride group (H&E ×8).

Figure 7. Stromal and epithelial infiltration with eosinophilic
leukocytes in the conjunctiva in the provocation term
of the dexamethasone sodium phosphate group (H&E
×40).

Figure 8. Intensive mononuclear inflammatory cell infiltration
with a lymphoid follicle in the conjunctiva and
infiltration of the conjunctiva epithelium by eosinophilic
leukocytes in the postprovocation term of the
dexamethasone sodium phosphate group (H&E ×40).

significant differences were only detected for the
postprovocation term in the CAPE and
dexamethasone sodium phosphate groups (P = 0.003
and P = 0.014, respectively) (Table 2).

Figure 6. Extensive and intensive mononuclear inflammatory cell
infiltration with lymphoid follicle formation in the
conjunctiva in the postprovocation term of the
olopatadine hydrochloride group (H&E ×10).
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Discussion
The popular folk medicine propolis (bee glue) is
alleged to possess broad-spectrum usage qualities,
including antimicrobial, antiinflammatory, and tumor
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growth inhibitor effects. Caffeic acid and analogs
extracted from propolis are reported to have
antibacterial,
antiviral,
antiinflammatory,
antiatherosclerotic, antioxidative, antiproliferative,
immunostimulatory, and neuroprotective properties
(4-10). To the best of our knowledge, this is the first
study that investigates the antiallergic properties of
CAPE.
The pathogenesis of ocular allergy involves various
mechanisms that lead to mast cell degranulation and
the release of chemical mediators. These mediators
reveal the symptoms and signs of allergic
conjunctivitis, such as redness, epiphora, and
chemosis, that occur as a result of increased vascular
permeability (1,3).. Ko et al. described the typical
findings of allergic conjunctivitis, including itching,
tearing, chemosis, and redness after the instillation of
compound 48/80 (12). They stressed that these
findings were observed 5-30 min (early period) and
1.5 h (late period) after the provocation. All symptoms
and signs disappeared within 24 h in their study. In
the present study, the acute allergic conjunctivitis
model was used as described by Ko et al. (12).
Olopatadine is one of the most recent drugs that
can be added to this particular class of antiallergic
agents. It displays antihistaminic and membranestabilizing properties, but also has effects on other
mediators involved in the allergic response. In
comparative studies, the H1 selectivity of olopatadine
was superior to that of other ocularly used
antihistamines studied, such as ketotifen,
levocabastine, antazoline, and pheniramine (13,14).
When Abelson and Greiner compared the effect of
olopatadine on itching and vascular permeability with
the effects of levocabastine, olopatadine was superior
to levocabastine (15). Schoch reported that ketotifen
was more effective in reducing the vascular
permeability of eyelids compared to olopatadine and
levocabastine in a conjunctivitis model in rats (16).
Ozturk et al. emphasized that topical lodoxamide was
more effective at reducing signs of allergic
conjunctivitis than sodium cromoglycate, but less
effective than dexamethasone (17). In our study, no
significant differences were found among the groups
with regard to suppression of allergic conjunctivitis.
However, dexamethasone showed partial superiority
to CAPE and olopatadine in reducing clinical scores.

Abelson and Udell have demonstrated the
presence of H2 receptors in human tissues (18).
Combined use of H1 and H2 antagonists has also
been shown to inhibit the conjunctival allergic
reaction caused by histamine (19). It is well known
that prostaglandins (PG) and arachidonic acid (AA)
metabolites are effective at increasing histamine
secretion and vascular permeability. Clinical studies
that document the effectiveness of prostaglandin
synthesis inhibitors, diclofenac sodium, and ketorolac
tromethamine on seasonal allergic conjunctivitis also
support this theory (20). Steroids prevent PG and AA
metabolites by inhibiting phospholipase, an enzyme
that decreases histamine secretion and vascular
permeability. Leukotriene inhibitors in active
anaphylaxis models and cyclooxygenase inhibitors
such as ketorolac and flurbiprophen were shown to be
ineffective in acute allergic conjunctivitis models (21).
Conversely, prolonged topical use of steroids may lead
to steroid-specific optic adverse reactions such as
secondary infection, glaucoma, or cataracts in
humans (22).
There were some limitations of our study. First, it
is well known that allergic conjunctivitis correlates
with significant changes in the levels of different
mediators in the lacrimal fluid. These mediators were
not included in this study. Second, rabbit conjunctiva
often shows cell clusters in quite normal conditions.
In addition, the punch biopsy might affect
histopathological results.
In conclusion, our data demonstrated that 1%
CAPE was as clinically efficacious as 0.1% olopatadine
and 0.1% dexamethasone. In this manner, 1% CAPE
may be a useful alternative to 0.1% olopatadine and
0.1% dexamethasone in the treatment of acute allergic
conjunctivitis. Further studies in larger groups are
needed to confirm these data.
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